CAR2219 CAR-T / Hebei Taihe Chunyu Biotech - LARVOL DELTA

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors (clinicaltrials.gov) - P1/2 | N=90 | Recruiting | Sponsor: Tianjin Medical University General Hospital

New P1/2 trial • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Affiliated Hospital to Academy of Military Medical Sciences

New P1/2 trial • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD22